The Agency for Health Care Policy and Research charged the McMaster Evidence-based Practice Center with conducting a comprehensive systematic review ofthe literature on the treatment ofattention-deficit hyperactivity disorder (ADHD), with input from various groups ofstakeholders. One strategy used to avoid duplication ofwork included a critical appraisal ofexisting systematic reviews and metaanalyses.
Prevailing opinions regarding the validity of ADHD vary, from those who regard it as a myth (4,5) to those who believe that underlying genetic and physiological evidence support its existence (6) . Several features of ADHD contribute to the controversy: 1) it is a clinical diagnosis for which there are no laboratory or radiological confirmatory tests or specific physical features; 2) diagnostic criteria have changed frequently; 3) there is no curative treatment, so patients require long-term therapies; 4) therapy often includes stimulant drugs that are thought to have abuse potential; and 5) the rates ofdiagnosis and oftreatment substantially differ across countries, particularly Britain, Australia, Canada, and the United States (US) (1, 2, 6, 7) . The debate around the existence of ADHD is compounded by important variations in estimates of prevalence and frequency with which comorbid disorders are identified in patients with ADHD.
Against this background, it is not surprising to find wide variation and controversy around the treatment of ADHD. In fact, the variability in treatments around North America led to the development of practice parameters by the American Academy of Child and Adolescent Psychiatry (AACAP) (1) and has motivated the American Academy of Pediatrics (AAP) to develop clinical practice guidelines. The American Psychiatric Association (APA) is currently contemplating how to use the available information in the development of quality improvement projects.
Since 1997, the Agency for Health Care Policy and Research (AHCPR) has been supporting initiatives that could facilitate the production of clinical practice guidelines and quality improvement tools and inform consensus conferences around ADHD. One of these efforts is a joint initiative involving the AAP and Technical Resources International Inc to gather and analyze evidence on the prevalence and diagnostic screening ofADHD.
In June 1997, the US Department ofHealth and Human Services announced the start of a new program through which AHCPR would award contracts to institutions in the US and Canada to serve as evidence-based practice centres (EPCs). The mission ofthese EPCs, of which McMaster University is one, is to review all the relevant scientific literature on health care topics assigned to them by AHCPR. The main task ofthe EPCs is to produce "evidence reports" that will serve as the scientific foundation for public and private sector organizations to develop clinical practice guidelines and other strategies for improving the quality of the health care services. The first set oftopics was nominated by a group ofacademic, public, and private sector organizations in response to a solicitation published by AHCPR in November 1996. In September 1997, the AHCPR charged the McMaster EPC to conduct a comprehensive systematic review of the literature on the treatment of ADHD. This topic was nominated by the AAP and the APA.
First, the McMaster EPC assembled a multidisciplinary research team, with participation of the nominating organizations (all members of the subcommittee of the AAP on ADHD and the Deputy Medical Director of the APA), consumer groups, local experts, the task order officer from the AHCPR, and research staff. This group engaged in multiple consultations and identified the following questions to be addressed by the evidence report: 1) What is the evidence from comparative studies on the effectiveness and safety, both short-and long-term, of pharmacological and nonpharmacological interventions for ADHD in children and adults? and 2) Are combined interventions more effective than individual interventions?
A formal critical appraisal ofexisting systematic reviews and metaanalyses on the treatment of ADHD would provide an excellent opportunity to avoid duplication of work and to make efficient use of the resources available. This article describes such a process, which was used as the basis for a full report of a state-of-the-art systematic review to be released in late 1999 (http://www.ahcpr.gov). The data reported here will help those interested in the role ofsystematic reviews and metaanalyses in guiding ADHD treatment decisions.
Methodology

Inclusion and Exclusion Criteria
To be included, an article had to meet all ofthe following criteria: • Description as a systematic review or metaanalysis, or a review article with a Methods section or a clear description of the search strategy (for example, Medline) used to identify individual studies. • Focus on the treatment ofADHD and, ifit included studies ofpatients with other conditions, a separate analysis for patients with ADHD. • Publication in a peer-reviewed journal, in any language.
Articles were excluded only if they did not meet all these criteria.
Search Strategy
Potentially eligible articles were identified using the following strategies: Bibliography of ADHD Reviews 1027
The search was updated at the end of August 1998 to include articles that appeared until August 1998.
Article Selection
Titles and abstracts of citations identified with the above search strategy were reviewed to determine whether or not they met the eligibility criteria. When titles or abstracts did not determine eligibility, full papers were obtained. Abstracts or full papers were obtained for each entry considered possibly relevant. The selection process was conducted by 3 reviewers independently. The final decision on the eligibility of each ofthe citations was made by consensus. Any differences that were not resolved by the reviewers were resolved by referring to the information in the full report.
Data Extraction
Data extraction forms were specially developed and tested for this project. After members of the research team were consulted and their suggestions incorporated, the forms were approved for content.
Data were extracted from each ofthe full reports by 2 reviewers independently. The extracted data were compared, and differences were resolved by consensus and by referring to the information in the original report.
The original reports were not masked because an empirical methodological study shows that masking is time-consuming and does not have an important impact on the results of systematic reviews (9) .
The following information was extracted from the articles:
1. General characteristics • Name of the first author.
• Publication type (for example, metaanalysis or systematic qualitative review); for metaanalyses, the statistical method used to combine the data. • Source of the review (bibliographic databases, reference list, personal bibliography). • Country of the review. • Language of publication. • Number of individual studies reviewed and age-group of subjects. 2. Generic methodological aspects • Overall methodological quality. This was assessed using the only validated tool available, the Oxman and Guyatt's Index of the scientific quality of research overviews (10) . This tool contains 10 questions, each with a numerical score (from 1 to 7) generated by a 7-point Likert scale, and produces reliable scores, even among individuals who have not been trained to use it. The items in the Index address issues related to the search for evidence, the selection ofstudies to include, the validity of included studies, methods of combining the findings ofincluded studies, and the support for conclusions made by the reviewers. The lower the score, the poorer the quality and the greater the likelihood of bias in the review (11). • Sources used by the reviewers to identify individual studies.
• Design characteristics of the individual studies included in the reviews (for example, randomized controlled trials, cohort studies, case-control studies, case series). • Language restrictions (for example, the review only included studies published in English). • Sources of financial support (reviews associated with industry may produce systematically different results [12] 
Data Synthesis
The extracted data were entered into a database (Microsoft Access for Windows 95 version 7.00), and evidence tables and descriptive statistics were produced to summarize the information extracted from the articles.
Data related to the questions formulated by the research team were emphasized, focusing on the amount and quality of the evidence provided by the reviews in the following categories:
• Studies with drug-drug comparisons of pharmacological interventions; • Placebo-controlled studies evaluating the effects oftricyclie antidepressants. • Studies comparing pharmacological with nonpharmacological interventions (drug versus nondrug studies). • Studies evaluating the effects of long-term therapies (> 12 weeks). • Studies evaluating therapies for ADHD in adults (patients older than 18 years of age). • Studies evaluating combination therapies given. • Studies evaluating adverse effects of pharmacological interventions.
Results
Thirty-one reports were identified as potentially eligible (2, 13--42) . Six of them were excluded because they were not specifically focused on ADHD (25, 27, 30, 32, 34, 36) , 4 were excluded because they were not centred on the treatment of 1028
The Canadian Journal of Psychiatry Vol 44, No 10 Quarterly: nonrandomized children (13) Overcoming Learning trials and case Difficulties series ADHD (26, 29, 31, 37) , 5 because they included selected studies rather than a comprehensive systematic review (28, 33, 38, 40, 41) , and 1 because it was not published in a peer-reviewed journal (42) . One report was an extensive review ofreviews on stimulant therapy in children with AD HD that did not focus specifically on systematic reviews and metaanalyses and which had not been updated for over 5 years (35, 43) . We were informed of a systematic review of stimulant treatment being conducted with support from the Canadian Coordinating Office ofHealth Technology Assessment, which is unpublished (39) .
Included Reviews
Thirteen review articles (2, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] , published in 11 different journals, met the inclusion criteria and were included in this review ( Table 1) . Ten of the reports were found in Medline, 2 in Psycinfo, and 1 in the personal collection of one of the investigators. All ofthe reports were written in English. The reviews were published from 1982 to 1998. Four were published in 1982 and 1983, with the remainder appearing after 1993. Ten were completed in the US, and 3 in Canada. Six of the reviews had 2 authors, while the number of authors in the remaining reviews varied from 1 to 6. The backgrounds of the corresponding authors varied. The number of studies re-Generic Methodological Aspects viewed by each article varied from 4 to 135, with 2 reviews
The quality scores obtained with Oxman and Guyatt's Index not reporting the number of articles studied. The range in age varied from 2 to 6, and2 reviews obtained more than 4 out on covered by the reviews was preschool to adult, with only 2 of possible points ( Table 2) . One of these reviews, however, those reviews addressing the treatment of ADHD in adults.
evaluated an instrument for measuring treatment outcomes,
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The Canadian Journal of Psychiatry Vol 44, No 10 (16); the other looked at the benefits of school-based interventions (13),
Only 5 reviews clearly stated the search methods used, and 3 of these were reasonably comprehensive searches. The period covered by the search was reported in only 4 reviews (1973-1995,1975-1997, 1971-1995, and 1983-1993) .
Eleven of the papers reported the criteria for including studies in the overview, but no papaer reported the strategies for avoiding bias in selecting studies. One author reported that study eligibility was decided by 2 individuals independently, with consensus. In 5 of the reviews, the type of studies that were included was not reported or was unclear; in the remainder, the type varied ( Table 1) .
Six of the reviews addressed the validity of the included papers, while just 3 ofthem reported the criteria used for assessing the validity of the included studies. Assessment of the reproducibility of the quality was reported in 1 review (20) , and incorporation of quality scores into the quantitative analysis was reported by none.
The primary outcome of the review was stated in 4 cases (2, 15, 16, 19) . All of the reviews reported the methods used to combine the findings of the relevant studies, although 1 review only partially reported this information (24) . Eight reviews based their results on statistical analyses (metaanalysis), while 5 were systematic qualitative reviews. The 8 metaanalysis papers reported using the following: weighted variables technique (20), Cohen's method and z scores and Cooper's method (23), Glass and Hedges' standardized mean difference (22), Cohen's d index (17), standardized mean difference (14, 15) and a combination of these methods, depending on the study design (13) . Just 2 reviews conducted a formal statistical evaluation of between-study heterogeneity (13, 16) . In 8 reviews, we judged that the findings were combined appropriately (13) (14) (15) (16) (17) 20, 22, 23) .
All of the papers supported their conclusions with the data and analysis presented in the article.
Three reviews restricted the papers included to those published in English only (2,16,21), 1 did not restrict inclusion based on language (14) , and the other 9 did not report this information (13, 15, (17) (18) (19) (20) (22) (23) (24) . The funding source of the reviews was not reported in 7 cases (15, 17, (19) (20) (21) 23, 24) , and the 6 that reported this information were funded by government (18), university (14), professional organization (2), charity (22), industry plus government (16) , and government plus university (13) .
ADHD-Specific Issues
Diagnosis. Three reviews reported MBD as the diagnostic model (2, 14, 20) , 5 reported hyperkinetic syndrome (2, (13) (14) (15) 20) , 4 reported ADD (2, 13, 16, 17) , and 6 used ADHD (2, 13, 16, 20, 22, 24) . Four reports were unclear about the diagnostic model used or did not report it (18, 19, 21, 23) . One review reported standardization of the diagnosis (16) . Only 4 papers referred to comorbid disorders: CD, anxiety disorder, depressive disorder, Tourette syndrome, mental Table 5 . Conclusions of reviews Systematic reviews are important tools for decision-makers (44) . A systematic review, ideally, includes strategies to times), positive social behaviour (3 times), global ratings of treatment effects (3 times), and academic outcomes (3 times). The remaining outcomes were mentioned once each. There were 20 adverse effects mentioned: growth suppression 3 times; each of tics, hepatic toxicity, global score, insomnia, and diminished appetite twice; and other adverse effects only once each.
Discussion
There was no mention offamily-related outcomes (for example, parenting skills, parental confidence, parental adjustment, family functioning) in any of the reviews. System-related outcomes (for example, cost of service delivery, cost ofmedication, cost of other services, or cost of educational resources) were not addressed.
All ofthe reviews stated a conclusion (Table 5 ). Four reviews supported the use of stimulants. One review supported MPH over placebo, one carbamazepine, and one supported the use of pharmacological interventions in general. One found the effect of pharmacological intervention variable. One review supported the use ofnonpharmacological school-based interventions. One each of the reviews discredited the Feingold hypothesis, the importance ofMPH's adverse effects, and the risk of hepatic failure with pemoline. (14) Kavale and Forness (15) Schachar and Tannock (18) Stein and others (22) Spencer and others (21) Ottenbacher and Cooper (17) Losier and others (16) Wilens and others (24) Thurber and Walker (23) Silva and others (20) Goldman and others (2) Of the nonpharmacological interventions mentioned in the reviews, placebo was addressed 4 times, tutoring or cognitive training 3 times, parent training twice, treatment classroom twice, and diet twice. There was 1 mention of each ofthe following: teacher training, psychotherapy, and support groups. There was no mention of family or marital therapy, socialskills training, EEG biofeedback, alternative therapy or drug holiday.
Three reports mentioned the role of combination therapies. They included combination of MPH with thioridazine, desipramine, fluoxetine, and parent management. Combinations of "stimulants" with "neuroleptics" and with "beta-blockers" were mentioned in 1 report. The reviews that mentioned combined interventions, however, did not provide a separate analysis of the combinations with the individual interventions.
There were 2 references to matters related to fidelity and monitoring of treatment. Drop-outs and adherence and compliance with treatment were mentioned once each (18, 20) .
Outcomes. Outcomes reported in the reviews can be seen in Table 4 . The most commonly addressed were hyperactivity (6 times), inattention (5 times), impulsivity (4 times), CD (3 retardation, and tics (21) ; CD, depressive disorder, and learning disorder (18) ; ODD, CD, and low IQ or mental retardation (13) ; and oppositional defiant behaviour, CD, anxiety, depression, learning disorder, Tourette syndrome, and low IQ (2). None of the reviews explored who made the diagnosis, the setting where the diagnosis was made, the treatment setting, or the predominant discipline of the researchers.
None of the reviews appeared to capture information on family characteristics, family structure, socioeconomic status, maternal education, paternal education, income, family functioning, or parental depression. Ethnocultural background was mentioned in 1 review (21) , and family history of DuPaul and Eckert (13) 1997 ADHD was reported in 1 case (2).
Treatment. Forty-five pharmacol- Sheveil and Schreiber ogical interventions were addressed (19) in the reviews. Only 7 drugs were mentioned more than twice: methylphenidate (MPH) (8 times), pemoline (7 times), imipramine (5 MA = metaanalysis; SQR = systematic qualitative review. times), dextroamphetamine (7 times), bupropion (3 times), caffeine (4 times), and chlorpromazine (4 times). The other 38 drugs were mentioned once or twice (Table 3) . minimize bias and to maximize precision and incorporates an explicit and detailed description of how it was conducted such that any interested reader could replicate it. Reports of systematic reviews should include clear research questions, criteria for inclusion or exclusion of primary studies, the process used to identify primary studies, the methods used to assess the methodological quality of the selected studies, and the methods used to extract and summarize the results ofprimary trials on which the conclusions are based (45) . At the end, the value of systematic reviews depends on their replicability, validity, precision, and relevance.
Most systematic reviews and metaanalyses on the treatment of ADHD have extensive flaws related to poor description of the methods used by the authors to identify, select, assess, and synthesize information, because most researchers in this area are not keeping up with recent methodological developments. Only 2 of the 13 reviews appraised had minor to minimal flaws. One of them reviewed the patterns of the Continuous Performance Test errors of omission and commission made by normal children and children with ADHD under no drug, placebo, and MPH. This review combined data from 26 studies to indicate that children with ADHD made more errors than normal children and that MPH reduced significantly the rate of errors (16) . The other review with minor flaws evaluated the effects of school-based interventions for ADHD. This review, which included data from 63 studies conducted during 1971-1995, concluded that school-based interventions for children with ADHD lead to significant behavioural benefits, regardless of the study design. It also found less robust effects for academic and clinical test performance (13) . Neither review addressed any ofthe questions selected by our multidisciplinary research team. Most of the remaining reviews addressed issues ofrelevance to clinicians, researchers, and policy-makers, but their methodological deficiencies made them prone to bias and limited their value as decisionmaking aids.
The methodological deficiencies found in the systematic reviews and metaanalyses on the treatment ofADHD are similar to those found in most other areas in health care. The areas neglected by the reviews on the treatment ofADHD are very similar to those found more than 10 years ago in a series of 50 medical review articles evaluated by Mulrow (44) and in more recent studies (8, 46) . The quality of the reviews does not seem to be improving over time. All the reviews included in this study had been published, suggesting that the referees and editors of the journals where they were published were also unaware ofthese basic requirements or did not believe in their importance.
Future reviewers have the opportunity not only to produce reviews of unprecedented high methodological quality in the areas covered by existing reviews but also to focus on issues that have not been addressed to date. At the McMaster EPC, for instance, the multidisciplinary research team will conduct systematic reviews to evaluate the short-and long-term roles of medications (particularly stimulant and antidepressant drugs), nondrug interventions, and combination therapy and Clinical Implications • Most systematic reviews and metaanalyses on the treatment of attention-deficit hyperactivity disorder (ADI-ID) have extensive methodological flaws, • The two reviews with minimal flaws indicated that children with ADHD made more errors than normal children (on Continuous Performance Test) and methylphenidate significantly reduced the number of errors and that school-based interventions for children with ADHD lead to significant behavioural benefit and have less robust effects for academic and clinical test performance.
Limitations
• The review was based on the information available in published reports, • There are very few findings of importance to clinicians, • The report does not describe a new review overcoming the limitations found on the available reviews, Such a review will be published elsewhere, selected adverse effects associated with stimulants and antidepressants. Other researchers, clinicians, peer reviewers, and journal editors should fmd our results and bibliography useful in guiding their decisions around future systematic reviews on the treatment of ADHD.
